Broadstreet Health Economics & Outcomes Research

How do you (really) feel about AI in your workplace?   At Broadstreet Health Economics & Outcomes Research, technology is integral to our work. Complex algorithms, detailed literature searches, code writing, data visualization … just a few of the tasks that involve sophisticated software, including automated tools.  That said, we are cautious about the use of Artificial Intelligence (AI).   We recently conducted an internal review to examine how this emerging technology could and should be used in our workstreams.   Despite the acceleration of machine learning (ML) and large language models (LLM) like Chat GPT, these tools have inherent flaws that require diligence in fact-checking and proof of evidence. Ultimately, we are committed to using AI only where it makes sense for efficiency and always in a supportive role, at the discretion and supervision of our expert team members. After all, it’s the humans who need to drive the strategy, evaluate results, build the narrative and interpret the results.   Learn more about our opinions on AI, including the Broadstreet HEOR Position Statement, in our latest blog post [linked below]. We were delighted to see our AI viewpoint is consistent with policy statements from ISPOR—The Professional Society for Health Economics and Outcomes Research and NICE - National Institute for Health and Care Excellence.   Tell us about your AI position.   #BroadstreetHEOR #HEOR #AI #ISPOR #NICE

Broadstreet Health Economics & Outcomes Research is 9 this week!

New research from Broadstreet Health Economics & Outcomes Research and Asthma Canada sheds a light on what people experiencing severe asthma are looking for from new treatments. #asthmaresearch #BroadstreetHEOR #AsthmaCanada

The Cerebellum journal recently published our article on the development of a new measure that better captures disease progression in patients with spinocerebellar ataxia. The partial least squares methodology allows for objective selection and weighting of candidate scale items based on their sensitivity to clinical decline. The resulting composite scale is therefore optimized to detect disease progression in the patient population of interest. #BroadstreetHEOR #SCACOMS

Thank you to Lon Castle, Lou Garrison, and Richard Rothman, MD, PhD for a fascinating panel at #ISPOR yesterday on the value of diagnostic testing when treatment is not available, adroitly moderated by Broadstreet’s own Karissa Johnston

Twelve Broadstreet research projects will be featured at ISPOR 2024 this year. Click below to find out more or come by and visit our posters if you’re going to be in Atlanta. #ISPORAnnual

To mark Rare Disease Day, we are shining a light on recessive dystrophic epidermolysis bullosa, a devastating, ultra-rare skin and connective tissue condition affecting thousands of people around the world. #rarediseaseday2024

Neil Hawkins, Evi Germeni and I recently spent some time looking into the extent and quality of qualitative, patient-based evidence submitted for health technology assessment. We invite you to read about our findings which have just been published in International Journal of Technology Assessment in Healthcare. HEHTA University of Glasgow #HTA #qualitativeresearch

Season's greetings from Broadstreet! Wishing you all a safe and happy holiday season.

We're looking for a Senior Biostatistician, for more details, click below: